Medication-Assisted Treatment (MAT)

Medication-assisted treatment (MAT), including opioid treatment programs (OTPs), combines behavioral therapy and medications to treat substance use disorders.

SAMHSA appoints eligible nonprofit organizations and governmental entities to be OTP accrediting bodies.

Access Form SMA-163: Application for Approval as Accreditation Body.

Find contact information for existing SAMHSA-Approved OTP Accrediting Bodies.

MAT for opioid addiction is subject to federal legislation, regulations, and guidelines, including DATA 2000 and federal regulation 42 CFR 8.

SAMHSA's Dear Colleague Letters offer providers of MAT services guidance on emerging issues related to opioid treatment.

Access Model Guidelines for State Medical Boards.

Learn more about special circumstances for providing buprenorphine.

To prescribe or dispense buprenorphine, physicians must qualify and apply for a waiver under the Drug Addiction Treatment Act of 2000 (DATA 2000).

Physicians can complete the Online Request for Patient Limit Increase.

Physicians are also required to complete buprenorphine training.

Learn more about how to:

Physicians can join the SAMHSA Buprenorphine Clinical Discussion WebBoard to ask and discuss questions on the clinical use of buprenorphine.

A combination of medication and counseling and behavioral therapy is effective in treating alcohol and opioid dependency.

Learn about the different medications used in MAT:

Find information on physical ailments often diagnosed in MAT patients. Also known as common comorbidities, these include viral hepatitis, HIV, and AIDS.

DPT oversees the dispensation of controlled narcotic medications for the treatment of substance use disorders.

Last Updated: 05/23/2016